OncogenPub Date : 2019-01-01DOI: 10.35702/onc.10017
L. Núñez-Naveira, C. Montero-Martínez, L. Mariñas-Pardo
{"title":"Non-Small Cell Lung Cancer Prognosis Based In A Cut-Off Value For Plasma Basic Fibroblast Growth Factor Expression","authors":"L. Núñez-Naveira, C. Montero-Martínez, L. Mariñas-Pardo","doi":"10.35702/onc.10017","DOIUrl":"https://doi.org/10.35702/onc.10017","url":null,"abstract":"Background: Angiogenesis is regulated by angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) that may be deregulated in lung cancer. The aim of this study was to find out a pattern of VEGF and bFGF protein expression in exhaled breath condensate (EBC) and serum of non-small cell lung cancer (NSCLC) patients and healthy volunteers (smokers and nonsmokers) to obtain early diagnostic values to discriminate initial stages of disease.","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69922343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2019-01-01Epub Date: 2019-06-28DOI: 10.35702/onc.10013
Leslie C Costello
{"title":"The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer.","authors":"Leslie C Costello","doi":"10.35702/onc.10013","DOIUrl":"10.35702/onc.10013","url":null,"abstract":"<p><p>Androgen-independent advanced prostate cancer is a terminal malignancy that generally results in death within five years. Its cause has been unknown, and a treatment did not exist. Prevailing views have mistakenly implicated impaired androgen receptor activity in the development of androgen-independent malignancy; which has deterred the existence of an effective treatment. Instead, recent reports have provided evidence that prolactin promotes the development and progression of androgen-independent malignancy; which follows androgen ablation treatment for androgen-dependent prostate cancer. That relationship dictates that a treatment for advanced prostate cancer should suppress the concentration plasma prolactin. This has been achieved with cabergoline (dopamine agonist; Dostinex) treatment of a patient that resulted in 88% decreased plasma prolactin, and terminated the malignancy. That likely represents the first effective treatment for advanced prostate cancer. It remains to establish if this treatment will be successful for other patients with advanced prostate cancer.</p>","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45430782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
OncogenPub Date : 2018-12-31DOI: 10.35702/onc.10001
A. Mahboob, Ramadan Algamal, Belal Suliman, R. Ajjour, M. Mattar
{"title":"Primary Renal Lymphoma: A Case Report","authors":"A. Mahboob, Ramadan Algamal, Belal Suliman, R. Ajjour, M. Mattar","doi":"10.35702/onc.10001","DOIUrl":"https://doi.org/10.35702/onc.10001","url":null,"abstract":"An 80-year-old female with a long-standing history of hypertension. She had a new onset of bilateral dull aching flank pain, fatigue, and hematuria. CBC and kidney function were within normal limits. Ultrasound revealed enlarged left kidney and to a lesser extent right kidney with bilateral hypoechoic ill-defined infiltrating masses indistinct from the renal parenchyma with retroperitoneal extension. The patient was referred for CECT as a superior modality for more precise details regarding the extension of the mass.","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45388061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}